Building on the promise of emerging therapies to deploy the body's "natural killer" immune cells to fight cancer, researchers at the University of Michigan Rogel Cancer Center and U-M College of Engineering have gone one step further.
Jan 28, 2021 10:45pm Johnson & Johnson is seeking a nod for amivantamab as a second-line treatment for lung cancer patients with a rare EGFR mutation, but the company is already working on moving the candidate into the front-line setting. (Janssen)
Johnson & Johnson’s EGFR-MET bispecific antibody is padding its case ahead of a potential FDA nod. The drug shrank tumors in 40% of lung cancer patients with a rare EGFR mutation and curbed tumor growth in nearly three-quarters of patients.
The phase 2 data, presented virtually at the World Conference on Lung Cancer (WCLC), come from 81 patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The patients’ cancer had spread beyond the lungs or couldn’t be treated with surgery and had gotten worse despite taking platinum chemotherapy.
Janssen: New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
FOR EU TRADE AND MEDICAL MEDIA ONLY Not for distribution in the UK and Benelux
The Janssen Pharmaceutical Companies of Johnson Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.
1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings showed robust activity and durable responses with a tolerable and manageable safety profile (Abstract #3031) in patients with NSCL
In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy. In line with uptake observed in prior studies and clinical practice, younger patients (